B. lactis BLa80 reduces eczema and respiratory infections in high-risk infants: 180-day RCT
Daily B. lactis BLa80 supplementation (5×10⁹ CFU) favored reduction of eczema (27.6% vs. 69.5%, RR 0.398) and upper respiratory tract infections (19.4% vs. 42.5%, RR 0.457) in high-allergy-risk infants compared to placebo.
Context
Eczema and respiratory infections are the primary early manifestations of the atopic march and impose substantial healthcare burden. Gut microbiome modulation by strain-specific probiotics is an active mechanistic hypothesis, but evidence remains heterogeneous. This RCT tests a specific strain with simultaneous clinical, microbiome, and fecal immunological outcomes.
What the study showed
Eczema incidence was 27.6% in the probiotic group vs. 69.5% in placebo (RR 0.398; p<0.001), an absolute risk reduction of 41.9 percentage points. Upper respiratory infections occurred in 19.4% vs. 42.5% (RR 0.457; p<0.001), absolute reduction of 23.1 p.p. The study did not report 95% CI for either RR. Fecal immune markers showed increased sIgA (p<0.001) and reduced calprotectin (p<0.001) in the probiotic group; absolute values and effect sizes were not provided in the available text.
How it was done
Double-blind, placebo-controlled RCT registered at ChiCTR2300074956; 360 participants enrolled over 180 days. Population restricted to formula-fed infants with elevated allergy risk, excluding breastfed infants, limiting generalizability.
Effect magnitude
RR 0.398 for eczema and RR 0.457 for URTI (both p<0.001); 95% CI not reported in available text. Absolute reductions of 41.9 and 23.1 p.p. are clinically large if confirmed with CI.
Limitations
Absence of 95% CI for primary outcomes prevents complete precision assessment. Risk of bias was not assessed using a standardized tool (RoB 2) in the available excerpt. Exclusive enrollment of high-risk formula-fed infants limits applicability to general-risk or breastfed populations. The 180-day follow-up does not support conclusions on long-term persistence or atopic march impact. Chinese registry (ChiCTR) without verifiable allocation concealment detail.
In clinical practice
Clinicians may consider B. lactis BLa80 for high-allergy-risk formula-fed infants, with expected reduction in eczema and URTI incidence during the supplementation period. 95% CI are unavailable, and strain-specific effects cannot be extrapolated to other Bifidobacterium strains. Awaiting full publication with safety data and intention-to-treat analysis is advisable.
What is still missing
RCTs including breastfed infants and general-risk populations are needed to extend applicability. Post-intervention follow-up ≥12 months is required to assess effect persistence and atopic march impact.